यूरोपीय संघ - रोमानियाई - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilate - carcinomul, celula renală - agenți antineoplazici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilate - carcinoma, renal cell - antineoplastic agents - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

eisai gmbh - mésilate de lenvatinib - carcinome, cellule rénale - agents antinéoplasiques - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilat - krabbamein, nýrnafrumur - Æxlishemjandi lyf - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

eisai gmbh - lenvatinibmesilat - karsinom, nyrecelle - antineoplastiske midler - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

eisai pharma ag - lenvatinibum - kapseln - lenvatinibum 4 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika

स्विट्ज़रलैंड - जर्मन - Swissmedic (Swiss Agency for Therapeutic Products)

eisai pharma ag - lenvatinibum - kapseln - lenvatinibum 10 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 4mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 10mg

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

eisai pharma ag - lenvatinibum - capsule - lenvatinibum 4 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika